{
    "nctId": "NCT01207635",
    "briefTitle": "Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer",
    "officialTitle": "Evaluation of Antiproliferative Effects of Arimidex in Ductal Lavage Fluid in Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Number of Patients with Antiproliferative Effects of Arimidex",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must have a history of breast cancer.\n* Patient must be scheduled to receive standard treatment with Arimidex for adjuvant hormonal management.\n* Patient must be willing to undergo a duct lavage.\n* Patient must sign an Informed Consent.\n\nExclusion Criteria:\n\n* None.",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}